<DOC>
	<DOCNO>NCT00630942</DOCNO>
	<brief_summary>The purpose study see safe effective minocycline treatment Primary Sclerosing Cholangitis ( PSC ) .</brief_summary>
	<brief_title>Minocycline Primary Sclerosing Cholangitis ( PSC )</brief_title>
	<detailed_description>The purpose study determine safety profile minocycline patient PSC compare effect minocycline baseline value follow parameter : symptom pruritus fatigue , liver biochemistry , Mayo Risk Score , development clinical progression complication liver disease .</detailed_description>
	<mesh_term>Cholangitis</mesh_term>
	<mesh_term>Cholangitis , Sclerosing</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<criteria>Both gender Females childbearing age must negative pregnancy test within 48 hour participation agreement practice contraception duration study . Age 18 year old &lt; 75 year old . History chronic cholestatic disease least 6 month duration . Serum alkaline phosphatase level least 1.5 time upper limit normal . Cholangiography demonstrate intrahepatic and/or extrahepatic biliary obstruction , beading , narrow consistent PSC . Liver biopsy consistent diagnosis PSC . Patient 's informed consent study participation . Treatment tetracycline , ursodeoxycholic acid , corticosteroid , colchicine , methotrexate , azathioprine , cyclosporine , chlorambucil , budesonide , pentoxifylline , pirfenidone , nicotine , tacrolimus , silymarin , vitamin E prednisone precede three month . Findings highly suggestive hepatobiliary disease etiology complicate PSC . Anticipated need liver transplantation one year determine Mayo model estimate &lt; 75 % one year survival without transplantation . Recurrent variceal bleeding , presence ascites , encephalopathy . Active drug alcohol use . Pregnancy . Breastfeeding . Serum creatinine 1.5 mg/dl . Prior history allergic reaction antibiotic belong tetracycline family . Any condition , opinion investigator , would interfere patient 's ability complete study safely successfully . Patients active inflammatory bowel disease ( IBD ) require specific treatment precede three month , except maintenance therapy 5ASA compound , individual involve trial evaluate experimental drug treatment IBD precede three month . Recurrent ascend cholangitis require hospitalization past year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>PSC</keyword>
</DOC>